Alzheimer’s Disease
NKMax: Expanded access, Treatment of Advanced Alzheimer’s type Dementia via autologous NK cell transfusion SNK01
Currently in Progress but Closed for Enrollment
FDA approved expanded access investigational new drug study to assess SNK01, a patented autologous NK cell culture technology with high CX3CR1 receptor expression to enable microglia to phagocytose abnormal proteins and regulate neuronal inflammation in patients with advanced stage Alzheimer’s type dementia. Sponsor - Dr. Vincent DeOrchis
Otsuka: Treatment of Agitation in patients with Alzheimers type Dementia
Open
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
Current in Progress but Closed for Enrollment
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease and small vessel vascular disease
Novo Nordisk: EVOKE Plus
Current in Progress but Closed for Enrollment
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease
Novo Nordisk: EVOKE
Roche: Graduate I Study
Study Closed
The GRADUATE I clinical study will assess how safe and effective an investigational drug is at slowing the progression of early (also known as ‘prodromal’) or mild Alzheimer’s disease.
Merck: Insomnia in Alzheimer’s Patients Study
Study Closed
This research study is evaluating whether the study medication Suvorexant is safe and effective, compared with placebo, in improving insomnia in patients with insomnia and Alzheimer’s disease. The study medication is approved for certain uses in the U.S. and Japan but is considered investigational for other uses and in other countries.
VTV Therapeutics: Steadfast Study
Study Closed
The STEADFAST Study is a clinical trial, or research study, that will evaluate a new investigational medication, Azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild-stage Alzheimer’s disease. Azeliragon works by blocking a receptor in the brain that binds to substances such as amyloid beta, a protein thought to contribute to the symptoms of Alzheimer’s disease.
Study Closed
The clinical trial will assess the efficacy and safety of verubecestat (MK-8931) compared to placebo during 78 week for Alzheimer’s Disease (AD). Participants may choose to participate in a long term double-blind extension phase for up an additional 260 weeks. Your participation in this study is completely voluntary